Domestic price of tremelimumab

Tremelimumab (tremelimumab) is a drug that binds to the protein CTLA-4 to help immune cells better kill cancer cells and is used to treat different types of cancer. Temsitumumab is used with durvalumab to treat adults with hepatocellular carcinoma (a type of liver cancer) that cannot be removed with surgery. It is also used with durvalumab and platinum chemotherapy to treat adult non-small cell lung cancer that has spread to other parts of the body and does not have abnormal EGFR or ALK genes. It is also used to treat other types of cancer.

Tesitumumab may blockCTLA-4 and help the immune system kill cancer cells. It is a monoclonal antibody and an immune checkpoint inhibitor also known as tremelimumab. Temsitumumab is only available by prescription, and treatment must be started and supervised by a doctor experienced in treating cancer. It is given by intravenous infusion (drip) and lasts about an hour. Treatment consists of up to 5 doses, but treatment may be permanently discontinued if the cancer worsens or if the patient develops severe side effects, such as anemia, nausea, neutropenia, fatigue, rash, thrombocytopenia, and diarrhea.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.